Latest news
Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial…
Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony
Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress
Debiopharm’s new agreement with the University of Geneva boosts scientific Innovation Hub in the Lemanic region of Switzerland through the…
Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124
7e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale
Debiopharm leads investment round for evidence-based digital cancer therapeutic app Mika to empower cancer patients
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.